New Logo.png
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
March 07, 2024 08:00 ET | Provectus Biopharmaceuticals Inc.
Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative HNSCC in vitro and in vivo KNOXVILLE, TN, March 07,...
Local Leader Paves the Way While Championing Diversity and Leadership for Women of Color
April 28, 2020 14:28 ET | Moffitt Cancer Center
TAMPA, FL, April 28, 2020 (GLOBE NEWSWIRE) -- Cathy Grant serves as Senior Director of Moffitt Cancer Center’s Diversity team and has led the diversity and inclusion efforts for the nationally...
Left to Right Dr. B. Lee Green , Dr. Douglas Letson, Dr. Sarah Hoffe, Dr. Larry R. Thompson, Dr. Jason Fleming
Moffitt Cancer Center and Ringling College to Bring Virtual Reality to Cancer Patients
September 27, 2019 14:15 ET | Ringling College of Art and Design
Technology collaboration to improve patient experience and enhance health care training capabilities TAMPA, Fla, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Cancer treatment is becoming more complex than...
Lixte Biotechnology Files an IND with the FDA to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center
October 09, 2018 09:45 ET | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has submitted an IND to the FDA to conduct a Phase 1b/2 trial of the safety...
Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome
August 21, 2018 09:45 ET | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has entered into a Clinical Trial Agreement and Exclusive License Agreement...
Tampa Medical Innovations Selected to Present IV STAT-Clip(TM) Technology at West Coast Medical Device Conference
June 04, 2014 09:23 ET | TaMI
TAMPA, FL--(Marketwired - Jun 4, 2014) - Tampa Medical Innovations, Inc. (TaMI) has been selected as one of the 10 semi-finalists in the MedTech Innovator program, which is part of the 22nd Annual...
Medical Device Development Group and Moffitt Cancer Center Form Tampa Medical Innovations to Commercialize Inventions
February 03, 2012 08:24 ET | Medical Device Development Group
TAMPA, FL--(Marketwire - Feb 3, 2012) - Medical Device Development Group, specialists in the commercialization of medical devices, has announced a joint venture with Moffitt Cancer Center. The new...